Home of Healthcare Listings

Nasdaq leads in the number of listings in the biotechnology and pharmaceutical sectors.

explore

Nasdaq is proud to be a partner to a global community of healthcare leaders, including 98% of U.S. listed biotech companies. Our listed clients choose Nasdaq for our index inclusion opportunities, marketing and visibility platform, and continued public policy advocacy work on behalf our of issuer community. Approximately 900 healthcare corporate clients and more than 450 biotech/pharma companies use our in-house shareholder engagement and intelligence tools and governance solutions (as of May 2019).

Nasdaq has a thriving index business for listed companies to gain exposure to passive investors, which includes the Nasdaq Biotechnology Index (NBI), a market capitalization weighted index focused specifically on the biopharmaceutical industry.

NBI logo stat
First Half of 2019 Biotech IPO Win Rate
100%
Additionally, 2018 was a record IPO year with 72 biotech IPOs raising approximately $8.4 billion in IPO proceeds.
Moderna IPO
Nasdaq leads with 100% Biotech IPO win rate
In the first half of 2019, 30 biopharmaceutical IPOs raised $2.9 billion in IPO proceeds on Nasdaq.
List on Nasdaq
First Half of 2019 Biotech IPO Win Rate
100%
Additionally, 2018 was a record IPO year with 72 biotech IPOs raising approximately $8.4 billion in IPO proceeds.

Largest Biotech-Pharma IPOs in 2019

BridgeBio Pharma

Nasdaq-listed: BBIO
IPO Market Value: $3.3B
Raise: $349M

Gossamer Bio, Inc

Nasdaq-listed: GOSS
IPO Market Value: $1.1B
Raise: $276M

Alector, Inc

Nasdaq-listed: ALEC
IPO Market Value: $1.23B
Raise: $176M

Envision a Future – Fueled by Innovation, Technology and Expertise.
Now, let’s get there. Select below.